New guidance warns of aspergillosis risk

By Mindo - 01st Mar 2018 | 83 views

<p class=”p1″><span class=”s1″>The recently-finalised document published </span>by the Health Protection Surveillance Centre <span class=”s1″>(HPSC) has noted that, in some cases, there are “major building projects occurring on existing hospital campuses where the population of immunocompromised patients is sig</span>nificant”. The guidelines are an updated document that was first issued in 2002.

<p class=”p1″><span class=”s1″>Prof Tom Rogers, Chair of the Aspergillosis Subcommittee, stated in his forward that there have been important changes in practice in re</span>lation to isolation facilities, antifungal therapies <span class=”s1″>and fungal diagnostics, as well as the emergence </span>of <em>A.fumigatus </em>strains with triazole resistance.

<p class=”p1″><span class=”s1″>The guidelines underline that hospital management must give sufficient notice to all interested parties including the infection prevention and control team of any planned activities before they start so that a risk assessment and preventive measures can be put in place to protect vulnerable patients. Moreover, contractors must agree to and sign a construction permit and be compliant with the </span>local infection prevention and control policy. <span class=”s1″>High-efficiency particulate air (HEPA)- filtered positive pressure facilities are pre- ferred for the protection of high- and very high-risk patients during major internal and non-containable external activities, accord</span>ing to the document. <span class=”s1″>In consultation with the clinical teams in</span>volved, consideration should also be given to <span class=”s1″>prescribing antifungal drug prophylaxis in </span>selected patients based on a risk assessment.

<p class=”p1″><span class=”s1″>Nosocomial outbreaks of aspergillosis </span>have become a well-recognised complication <span class=”s1″>of construction, demolition or renovation work in or near hospital wards in which im</span>munosuppressed patients are cared for.

<p class=”p1″><span class=”s1″>Haematopoietic stem cell transplant (HSCT) recipients are the population at highest risk of invasive aspergillosis (IA). Other immunosuppressive conditions have frequently been reported as risk factors for construction-related nosocomial fungal infections: graft–versus-host disease requiring treatment, prolonged neutropaenia following cytotoxic chemotherapy, prolonged use of antibiotics, steroid ther</span>apy, and tumour necrosis factor α antagonists.

<p class=”p1″><span class=”s1″>“As the complexity of therapeutics increases and the survival rates from oncologic and haematologic conditions improves, it is likely that more patients will be at risk of </span>IA,” it states.

Leave a Reply

Latest
Latest Issue
Irish Healthcare
The Medical Independent 6th October 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read